Tripadvisor Inc Common Stock vs Zoetis Inc — how do they compare? Tripadvisor Inc Common Stock trades at $10.89 (market cap $1.28B), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 24.3× Tripadvisor Inc Common Stock's market cap, and Zoetis Inc pays a 2.81% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| TRIP | ZTS | |
|---|---|---|
Market Cap | $1.28B | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $19.14 | $156.76 |
52-Week Low | $9.24 | $71.91 |
Enterprise Value | $1.33B | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Tripadvisor (TRIP) trades at $10.695, down 0.79% on the day, reflecting persistent pressure from recent earnings misses and competitive challenges. The stock shows a bearish technical bias with weak moving averages, though oversold RSI levels hint at potential near-term support. Fundamentally, revenue growth is modest at $1.89B in 2025, but net margins remain thin at 0.27%, and a high P/E of 127.18 signals elevated expectations relative to earnings. The pending $700M sale of TheFork provides a liquidity boost but does not fully offset core business headwinds from AI-driven travel competition.
Outlook is cautious; while the stock trades below the consensus price target of $13.29, offering theoretical upside, investor sentiment is tempered by consecutive earnings misses and market share erosion. Key risks include stiff competition from AI travel tools, macroeconomic sensitivity, and execution challenges in revitalizing growth. Analysts are predominantly neutral (62.5% Hold), suggesting limited conviction in near-term catalysts despite the stock's current discount to target.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
Latest headlines on both assets
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →